[5-min read] Q&A with Payton Nyquvest, Founder & Executive Chair
[3-min read] Psychedelic facilitators explain shadow work.
[5-min read] New study demonstrates psilocybin's anti-aging effects.
[5-min read] Q&A with Simon Ruffell, Researcher & Psychiatrist
[3-min read] Facilitators weigh in on psychedelics for addiction recovery.
[5-min read] Study shows a moderate dose of psilocybin relieves symptoms of OCD.
[5-min read] Q&A with Heather Jackson, Cofounder & President
[3-min read] Psychedelic facilitators offer advice on microdosing for creativity.
[5-min read] Psilocybin therapy provides sustained relief from depression in 5-year follow-up study.
[6-min read] Q&A with Jonathan Dickinson, Founder & CEO
[3-min read] Psychedelic facilitators share healthy ways to work through strong emotions.
[5-min read] Compass Pathways achieves the primary endpoint in its first Phase 3 trial.
